Vanderbilt-Ingram Cancer Center — Nashville, Tennessee

Public research footprint of Vanderbilt-Ingram Cancer Center, compiled from the ClinicalTrials.gov public registry.

766

Registered studies

153

Active

Recruiting now

458

Completed

141

Stopped or withdrawn

Most-studied conditions

Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type · Recurrent Ovarian Carcinoma · Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma · Metastatic Bladder Large Cell Neuroendocrine Carcinoma

Recently updated registry entries

NCT02224781 — Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and… (Active Not Recruiting)
NCT01272037 — Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in… (Active Not Recruiting)
NCT02003222 — Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Vanderbilt-Ingram Cancer Center?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.